Osteosarcoma - historical

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

Back to Top

The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. As a general rule, this includes the inferior arm(s) of a randomized study, unless said regimens continue to be recommended by trustworthy sources such as the NCCN Guidelines. Is there a regimen missing from this list? See the main osteosarcoma page for current regimens.

8 regimens on this page
8 variants on this page


Neoadjuvant therapy

MA-BCD

MA-BCD: High-dose Methotrexate, Adriamycin (Doxorubicin), Bleomycin, Cyclophosphamide, Dactinomycin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Winkler et al. 1984 (COSS-80) 1979-1982 Phase 3 (C) MAP Did not meet primary endpoint of CDF rate

Note: The exact schedule is unclear based on limited/conflicting information in the reference. For example, Figure 1 appears to depict high-dose methotrexate starting 2 weeks after adriamycin, but the text says that methotrexate begins after a 3-week rest period. Additionally, the diagram in Figure 1 implies that the later therapies are given 4 times (once, then repeated x 3 cycles), but based on the cumulative doses listed, they are only given for a total of 3 cycles. The optional interferon arm is omitted given lack of benefit seen in the study.

Chemotherapy

  • Doxorubicin (Adriamycin) as follows:
    • Cycles 1, 3, 4: 45 mg/m2 IV bolus once per day on days 1 & 2
    • Cycle 2: 45 mg/m2 IV bolus once per day on days 15 & 16 (delayed during cycle 2 until after surgery)
  • Methotrexate (MTX) as follows:
    • Cycle 1: 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once per day on days 22 & 29
    • Cycles 2 to 4: 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once per day on days 1, 8, 29, 36
    • MTX is dissolved at a concentration of 20,000 mg/L in a solution containing 5% glucose
  • Bleomycin (Blenoxane) as follows:
    • Cycle 1: 12 mg/m2 IV bolus once per day on days 36 & 37
    • Cycles 2 to 4: 12 mg/m2 IV bolus once per day on days 43 & 44
  • Cyclophosphamide (Cytoxan) as follows:
    • Cycle 1: 600 mg/m2 IV bolus once per day on days 36 & 37
    • Cycles 2 to 4: 600 mg/m2 IV bolus once per day on days 43 & 44
  • Dactinomycin (Cosmegen) as follows:
    • Cycle 1: 0.45 mg/m2 IV bolus once per day on days 36 & 37
    • Cycles 2 to 4: 0.45 mg/m2 IV bolus once per day on days 43 & 44

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO every 6 hours x 12 hours once per day, starting 24 hours after the completion of each methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
  • Sodium bicarbonate urine alkalinization prior to high-dose methotrexate
  • Normal saline 4.5 L/m2 on day 1 after methotrexate; NS 3 L/m2 on day 2, with adjustments made to keep urine pH greater than 7.4

8-week cycle for 4 cycles, with surgery done during cycle 2 before doxorubicin; surgery is done 9 to 18 weeks after the start of chemotherapy

References

  1. COSS-80: Winkler K, Beron G, Kotz R, Salzer-Kuntschik M, Beck J, Beck W, Brandeis W, Ebell W, Erttmann R, Göbel U, Havers W, Henze G, Hinderfeld L, Höcker P, Jobke A, Jürgens H, Kabisch H, Preusser P, Prindull G, Ramach W, Ritter J, Sekera J, Treuner J, Wist G, Landbeck G. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. J Clin Oncol. 1984 Jun;2(6):617-24. link to original article contains dosing details in manuscript PubMed

M-BCD

M-BCD: High-dose Methotrexate, Bleomycin, Cyclophosphamide, Dactinomycin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Winkler et al. 1988 (COSS-82) 1982-1984 Phase 3 (C) MAP Inferior ORR

Note: The exact schedule is unclear based on limited information in the reference, as schedule of doses is primarily extrapolated from Figure 1, which does not contain clear delineations in time.

Chemotherapy

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO every 6 hours x 12 hours once per day on days 16 & 23, starting 24 hours after the completion of methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
  • Sodium bicarbonate urine alkalinization prior to high-dose methotrexate
  • Normal saline 4.5 L/m2 on day 1 after methotrexate; NS 3 L/m2 on day 2, with adjustments made to keep urine pH greater than 7.4

35-day cycle for 2 cycles

Subsequent treatment

  • Surgery, then risk-adapted treatment:
    • COSS-82, patients who had a good response: Adjuvant M-BCD
    • COSS-82, patients who had a poor response: Adjuvant AP

References

  1. COSS-82: Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. link to original article contains dosing details in manuscript PubMed

Adjuvant therapy

Doxorubicin monotherapy

Regimen

Study Evidence
Cortes et al. 1974 Non-randomized

Preceding treatment

Chemotherapy

4- to 6-week cycle for 6 cycles

References

  1. Cortes EP, Holland JF, Wang JJ, Sinks LF, Blom J, Senn H, Bank A, Glidewell O. Amputation and adriamycin in primary osteosarcoma. N Engl J Med. 1974 Nov 7;291(19):998-1000. link to original article contains dosing details in abstract PubMed

IP-BCD

IP-BCD: Ifosfamide, Platinol (Cisplatin), Bleomycin, Cyclophosphamide, Dactinomycin

Regimen

Study Dates of enrollment Evidence
Winkler et al. 1988 (COSS-82) 1982-1984 Non-randomized part of phase 3 RCT

Preceding treatment

Chemotherapy

Supportive therapy

  • Mesna (Mesnex) 2000 mg/m2 IV over 23.5 hours once per day on days 1 to 5, given second, with ifosfamide, then 2000 mg/m2/day IV continuous infusion over 48 hours, started on day 6 (total dose: 14,000 mg/m2)
  • Mannitol given with cisplatin; no further details provided

35-day cycle for 3 cycles

References

  1. COSS-82: Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. link to original article contains dosing details in manuscript PubMed

MA-BCD/AP

MA-BCD/AP: High-dose Methotrexate, Adriamycin (Doxorubicin), Bleomycin, Cyclophosphamide, Dactinomycin alternating with Adriamycin (Doxorubicin) & Platinol (Cisplatin)

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Link et al. 1986 1982-1984 Phase 3 (E-esc) No further treatment Superior RFS

Preceding treatment

Chemotherapy, MA-BCD portion

Chemotherapy, AP portion

References

  1. Link MP, Goorin AM, Miser AW, Green AA, Pratt CB, Belasco JB, Pritchard J, Malpas JS, Baker AR, Kirkpatrick JA, Ayala AG, Shuster JJ, Abelson HT, Simone JV, Vietti TJ. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986 Jun 19;314(25):1600-6. link to original article PubMed

M-BCD

M-BCD: High-dose Methotrexate, Bleomycin, Cyclophosphamide, Dactinomycin

Regimen

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Eilber et al. 1987 1981-1984 Randomized (E-esc) Observation Seems to have superior OS
Winkler et al. 1988 (COSS-82) 1982-1984 Non-randomized part of phase 3 RCT

Note: The exact schedule is unclear based on limited information in the references; schedule of doses is primarily extrapolated from Figure 1 of Winkler et al. 1988, which does not contain clear delineations in time.

Preceding treatment

Chemotherapy

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO every 6 hours x 12 hours once per day on days 16 & 23, starting 24 hours after the completion of methotrexate infusion; additional leucovorin used for delayed methotrexate elimination
  • Sodium bicarbonate urine alkalinization prior to high-dose methotrexate
  • Normal saline 4.5 L/m2 on day 1 after methotrexate; NS 3 L/m2 on day 2, with adjustments made to keep urine pH greater than 7.4

35-day cycle for 2 cycles

References

  1. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987 Jan;5(1):21-6. link to original article PubMed
    1. Update: Bernthal NM, Federman N, Eilber FR, Nelson SD, Eckardt JJ, Eilber FC, Tap WD. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma. Cancer. 2012 Dec 1;118(23):5888-93. Epub 2012 May 30. link to original article PubMed
  2. COSS-82: Winkler K, Beron G, Delling G, Heise U, Kabisch H, Purfürst C, Berger J, Ritter J, Jürgens H, Gerein V, Graf N, Russe W, Gruemayer ER, Ertelt W, Kotz R, Preuzzer P, Prindull G, Brandeis W, Landbeck G. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988 Feb;6(2):329-37. link to original article contains dosing details in manuscript PubMed

Methotrexate & Vincristine

Regimen

Study Dates of enrollment Evidence
Jaffe et al. 1974 1972-06 to NR Non-randomized

Preceding treatment

Chemotherapy

Supportive therapy

14-day cycle until therapeutic goal achieved, then 21-day cycle for up to 33 cycles (2 years total)

References

  1. Jaffe N, Frei E 3rd, Traggis D, Bishop Y. Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. N Engl J Med. 1974 Nov 7;291(19):994-7. link to original article contains dosing details in manuscript PubMed

Relapsed, refractory, or metastatic

Doxorubicin monotherapy

Regimen

Study Evidence
Cortes et al. 1972 Non-randomized, fewer than 20 pts

Chemotherapy

References

  1. Cortes EP, Holland JF, Wang JJ, Sinks LF. Doxorubicin in disseminated osteosarcoma. JAMA. 1972 Sep 4;221(10):1132-8. link to original article PubMed

MAPifn [COG AOST0331]

Study Dates of enrollment Evidence
Marina et al. 2019 (COG AOST0331) 2005-04-14 to 2011-06-30 Non-randomized part of phase 3 RCT

Note: Induction is received by all patients and consists of 2 cycles of MAP. The remainder of this protocol is for good responders.

Induction

Chemotherapy

  • Cisplatin (Platinol) 60 mg/m2 IV infusion over 4 hours, started on day 1 of weeks 1 and 6
  • Doxorubicin (Adriamycin) 37.5 mg/m2/day (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Weeks 1 and 6
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 4, 5, 9, and 10.

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

10-week course


Consolidation, Cycles 3-4

Chemotherapy

  • Cisplatin (Platinol) 60 mg/m2 IV infusion over 4 hours, started on day 1 of weeks 12 and 17
  • Doxorubicin (Adriamycin) 37.5 mg/m2/day (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Weeks 12 and 17.
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 15, 16, 20, and 21.

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

10-week course


Consolidation, Cycles 5-6

Chemotherapy

  • Doxorubicin (Adriamycin) 37.5 mg/m2/day (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Weeks 22 and 26.
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 24, 25, 28, and 29

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

10-week course


Maintenance, Weeks 30-104

Note: Peginterferon alfa-2b dose is increased only if the starting dose is well tolerated.

Immunotherapy

  • Peginterferon alfa-2b (Sylatron) as follows:
    • Cycles 1 to 4: 0.5 mcg/kg (maximum dose of 50 mcg) SC once on day 1
    • Cycles 5 to 75: 1 mcg/kg (maximum dose of 100 mcg) SC once on day 1

7-day cycle for 75 cycles

References

  1. EURAMOS-1 poor response: Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. Epub 2016 Aug 25. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00134030

MAPIE [COG AOST0331]

Study Dates of enrollment Evidence Comparator Comparative Efficacy
Marina et al. 2016 (EURAMOS-1 poor response) 2005-2011 Phase 3 (E-esc) MAP Did not meet primary endpoint of EFS

Note: Induction is received by all patients and consists of 2 cycles of MAP; subsequent treatments in this protocol are for poor responders.

Induction

Chemotherapy

  • Cisplatin (Platinol) 60 mg/m2 IV infusion over 4 hours, started on day 1 of weeks 1 and 6
  • Doxorubicin (Adriamycin) 37.5 mg/m2/day (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Weeks 1 and 6
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 4, 5, 9, and 10.

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

10 Week course


Consolidation, MAPIE Cycles 3 and 7

Chemotherapy

  • Cisplatin (Platinol) 60 mg/m2 IV infusion over 4 hours, started on day 1 of weeks 12 and 28
  • Doxorubicin (Adriamycin) 37.5 mg/m2/day (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Weeks 12 and 28.
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 15 and 31.

Supportive therapy

  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

5-Week Courses


Consolidation, MAP Cycles 4, 6, and 8

Chemotherapy

  • Ifosfamide (Ifex) 2.8 g/m2/dose IV over 4 hours once per day on days 1 through 5 of weeks 16, 24, and 32.
  • Etoposide (Vepesid) 100 mg/m2/dose IV over 60 minutes once per day on days 1 through 5 of weeks 16, 24, and 32.
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 19, 27, and 35.

Supportive therapy

  • Mesna (Mesnex) 2.8 g/m2/24 hours IV continuous infusion over 24 hours on days 1 through 5 of weeks 16, 24, and 32.
  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

5-Week Courses


Consolidation, MAP Cycle 5

Chemotherapy

  • Doxorubicin (Adriamycin) 37.5 mg/m2/day (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Week 20.
  • Ifosfamide (Ifex) 3 g/m2/dose IV over 4 hours once per day on days 1, 2, and 3 of weeks 20.
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 23.

Supportive therapy

  • Mesna (Mesnex) 3 g/m2/24 hours IV continuous infusion over 24 hours on days 1, 2, and 3 of weeks 20.
  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

5-Week Courses


Consolidation, MAP Cycle 9

Chemotherapy

  • Doxorubicin (Adriamycin) 37.5 mg/m2/day (total dose is 75 mg/m2 given as a 48 hour infusion) on days 1 to 2 of Week 36.
  • Ifosfamide (Ifex) 3 g/m2/dose IV over 4 hours once per day on days 1, 2, and 3 of weeks 36.
  • Methotrexate (MTX) 12,000 mg/m2 (maximum dose of 20,000 mg) IV over 4 hours once on day 1 of weeks 39 and 40.

Supportive therapy

  • Mesna (Mesnex) 3 g/m2/24 hours IV continuous infusion over 24 hours on days 1, 2, and 3 of weeks 36.
  • Leucovorin (Folinic acid) 15 mg/m2 PO or IV every 6 hours beginning 24 hours after the beginning of the methotrexate infusion and continuing until the serum methotrexate level is less than 0.1 μM.

5-Week Courses

References

  1. EURAMOS-1 poor response: Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD, Hook JM, Arndt C, van den Berg H, Brennan B, Brichard B, Brown KL, Butterfass-Bahloul T, Calaminus G, Daldrup-Link HE, Eriksson M, Gebhardt MC, Gelderblom H, Gerss J, Goldsby R, Goorin A, Gorlick R, Grier HE, Hale JP, Hall KS, Hardes J, Hawkins DS, Helmke K, Hogendoorn PC, Isakoff MS, Janeway KA, Jürgens H, Kager L, Kühne T, Lau CC, Leavey PJ, Lessnick SL, Mascarenhas L, Meyers PA, Mottl H, Nathrath M, Papai Z, Randall RL, Reichardt P, Renard M, Safwat AA, Schwartz CL, Stevens MC, Strauss SJ, Teot L, Werner M, Sydes MR, Whelan JS. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Oct;17(10):1396-1408. Epub 2016 Aug 25. link to original article link to PMC article contains dosing details in manuscript PubMed NCT00134030
Retrieved from "https://hemonc.org/w/index.php?title=Osteosarcoma_-_historical&oldid=84661"